Table 3.
Baseline Characteristics of Successful Versus Unsuccessful AF Ablated Patients in Ablated Group
| Overall Cohort | PSM Cohort | |||||
|---|---|---|---|---|---|---|
| SR Group (n=257) | Recurrent Group (n=151) | P Value | SR Group (n=116) | Recurrent Group (n=116) | P Value | |
| Age, y | 45.8±14.4 | 47.2±14.6 | 0.363 | 44.4±14.8 | 46.7±14.4 | 0.469 |
| Male | 101 (39.3) | 62 (41.1) | 0.754 | 47 (40.5) | 47 (40.5) | 1.000 |
| BSA, m2 | 1.70±0.24 | 1.70±0.26 | 0.914 | 1.70±0.23 | 1.70±0.27 | 0.959 |
| BMI, kg/m2 | 22.2±3.8 | 22.4±3.8 | 0.739 | 21.9±3.6 | 22.4±3.8 | 0.343 |
| NYHA class | 2.9±0.7 | 2.9±0.7 | 0.924 | 2.9±0.7 | 2.9±0.7 | 0.923 |
| Smoking | 67 (26.1) | 50 (33.1) | 0.298 | 37 (31.9) | 31 (26.7) | 0.471 |
| Diabetes mellitus | 35 (13.6) | 15 (9.9) | 0.348 | 13 (11.2) | 12 (10.3) | 1.000 |
| Hypertension | 64 (24.9) | 46 (30.5) | 0.248 | 32 (27.6) | 34 (29.3) | 0.884 |
| Stroke | 8 (3.1) | 10 (6.6) | 0.132 | 6 (5.2) | 6 (5.2) | 1.000 |
| CAD | 40 (15.6) | 25 (16.6) | 0.781 | 17 (14.7) | 19 (16.4) | 0.856 |
| COPD | 13 (5.1) | 8 (5.3) | 0.801 | 9 (7.8) | 6 (5.2) | 0.595 |
| CRI | 3 (1.2) | 3 (2.0) | 0.674 | 3 (2.6) | 3 (2.6) | 1.000 |
| CHADS2 score | 0.74±1.38 | 0.86±1.50 | 0.391 | 0.88±1.53 | 0.88±1.42 | 0.722 |
| EuroSCORE | 0.78±1.09 | 0.69±1.03 | 0.416 | 0.74±1.17 | 0.71±1.00 | 0.809 |
| AF duration, months | 2.8±0.8 | 2.8±0.7 | 0.343 | 2.8±0.7 | 2.8±0.7 | 0.647 |
| Etiology | ||||||
| Rheumatic | 195 (75.9) | 116 (76.8) | 0.904 | 87 (75.0) | 87 (75.0) | 1.000 |
| Degenerative | 39 (15.2) | 20 (13.2) | 0.663 | 20 (17.2) | 18 (15.5) | 0.859 |
| Endocarditis | 14 (5.4) | 10 (6.6) | 0.666 | 6 (5.2) | 7 (6.0) | 1.000 |
| Functional | 9 (3.5) | 5 (3.3) | 1.000 | 3 (2.6) | 4 (3.4) | 1.000 |
| Medication | ||||||
| ACEI | 53 (20.6) | 31 (20.5) | 1.000 | 22 (19.0) | 24 (20.7) | 0.869 |
| ARB | 17 (6.6) | 7 (4.6) | 0.516 | 7 (6.0) | 6 (5.2) | 1.000 |
| CCB | 7 (2.7) | 3 (2.0) | 0.751 | 3 (2.6) | 3 (2.6) | 1.000 |
| Beta‐blocker | 36 (14.0) | 20 (13.2) | 0.882 | 15 (12.9) | 16 (13.8) | 1.000 |
| Digitalis | 52 (20.2) | 38 (25.2) | 0.732 | 28 (24.1) | 22 (19.0) | 0.425 |
| Diuretics | 55 (21.4) | 27 (17.9) | 0.443 | 23 (19.8) | 21 (18.1) | 0.867 |
| Amiodarone | 21 (8.2) | 9 (6.0) | 0.440 | 8 (6.9) | 7 (6.0) | 1.000 |
| LVESD, mm | 35.2±8.2 | 35.6±19.7 | 0.791 | 35.9±8.4 | 34.6±8.3 | 0.234 |
| LVEDD, mm | 51.7±9.6 | 50.7±9.1 | 0.330 | 52.0±9.7 | 51.3±9.4 | 0.613 |
| sPAP, mm Hg | 40.8±8.5 | 40.0±9.0 | 0.356 | 40.6±8.7 | 40.9±9.0 | 0.653 |
| LAD, mm | 55.5±13.0 | 55.5±12.1 | 0.956 | 57.0±13.7 | 55.7±12.7 | 0.453 |
| LVEF, % | 58.4±8.0 | 59.0±7.8 | 0.472 | 58.1±8.6 | 58.2±8.1 | 0.881 |
| RAA, mm2 | 19.3±4.2 | 19.9±4.4 | 0.170 | 19.6.5±3.9 | 19.8±4.4 | 0.745 |
| RVSI | 1.8±0.4 | 2.0±0.4 | 0.000 | 1.9±0.4 | 1.9±0.4 | 0.435 |
| RVFAC, % | 41.9±6.1 | 43.8±6.4 | 0.003 | 43.4±6.1 | 43.4±6.1 | 0.949 |
| TAD, cm | 37.0±3.7 | 36.7±3.5 | 0.566 | 36.6±3.6 | 36.6±3.5 | 0.991 |
| TR grade | 1.1±0.7 | 1.1±0.7 | 0.698 | 1.1±0.7 | 1.1±0.6 | 0.920 |
| CABG | 13 (5.1) | 6 (4.0) | 1.000 | 4 (3.4) | 6 (5.2) | 0.748 |
| MV repair | 28 (10.9) | 12 (7.9) | 0.391 | 7 (6.0) | 12 (10.3) | 0.339 |
| MV replacement | 229 (89.1) | 139 (92.1) | 0.391 | 109 (94.0) | 104 (89.7) | 0.339 |
| Anuloplasty ring | 28 (10.9) | 12 (7.9) | 0.421 | 7 (6.0) | 12 (10.3) | 0.487 |
| Mechanic valve | 168 (65.4) | 96 (63.6) | 0.421 | 76 (65.5) | 73 (62.9) | 0.487 |
| Bioprosthetic valve | 61 (23.7) | 43 (28.5) | 0.421 | 33 (28.4) | 31 (26.7) | 0.487 |
| CPB, minute | 113.0±35.6 | 103.4±40.2 | 0.012 | 106.8±35.7 | 107.1±39.1 | 0.943 |
| ACT, minute | 74.2±7.6 | 68.1±29.9 | 0.035 | 69.8±27.2 | 70.3±29.1 | 0.891 |
ACEI indicates angiotensin‐converting enzyme inhibitor; ACT, aortic clamp time; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCB, calcium‐channel blocker; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CRI, chronic renal insufficiency; LAD, left atrial diameter; LVEDD, left ventricle end‐diastolic dimension; LVEF, left ventricle ejection fraction; LVESD, left ventricle end‐systolic dimension; MV, mitral valve; NYHA, New York Heart Association; PSM, propensity‐score matching; RAA, right atrial area; RVFAC, right ventricle fractional area change; RVSI, right ventricle sphericity index; sPAP, pulmonary artery systolic pressure; SR, sinus rhythm; TAD, tricuspid annulus diameter; TR, tricuspid regurgitation.